EIF3I

Eukaryotic translation initiation factor 3 subunit I · Q13347 · EIF3I on Sugi Atlas →

0 patent compounds predicted against EIF3I, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EIF3I by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer PHASE1/PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib nanCOMPLETED
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Protein Balance in Protein Supplemented Elderly Patients: Acute Study With Protein-tracer-techniques nanWITHDRAWN
Identification of miRNAs Associated With Gender Difference in Osteoarthritis Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EIF3I binder may also engage these)

ProteinNameSimilarity
B0BNA7 1.000 B0BNA7 →
Q9QZD9 1.000 Q9QZD9 →
Q5R7R2 1.000 Q5R7R2 →
Q5E966 1.000 Q5E966 →
B5FZ19 1.000 B5FZ19 →
Q66J51 1.000 Q66J51 →
Q5IH81 1.000 Q5IH81 →
Q5EBE8 1.000 Q5EBE8 →
Q7ZV55 0.997 Q7ZV55 →
Q4WX90 0.996 Q4WX90 →
B0XYC8 0.995 B0XYC8 →
Q0CXH9 0.995 Q0CXH9 →
Q1HPW4 0.994 Q1HPW4 →
A1CJY4 0.994 A1CJY4 →
A1D7I5 0.993 A1D7I5 →
A6RUL1 0.993 A6RUL1 →
A7EF03 0.993 A7EF03 →
B3N4C7 0.993 B3N4C7 →
Q38884 0.992 Q38884 →
P79083 0.992 P79083 →
B4KGX9 0.991 B4KGX9 →
B4GSH1 0.991 B4GSH1 →
Q7RXH4 0.991 Q7RXH4 →
Q5B8Y3 0.991 Q5B8Y3 →
O02195 0.991 O02195 →
B4LUA5 0.990 B4LUA5 →
A2QEV8 0.990 A2QEV8 →
B4Q354 0.989 B4Q354 →
Q2UQ34 0.989 Q2UQ34 →
B0XFT7 0.989 B0XFT7 →